Dow has introduced another product in its suite of 2,4-D-resistant GE seeds. First corn, now soy. Both products are bad ideas, and — should USDA approve them — will dramatically drive up the use of this antiquated, dangerous herbicide.
Scientists warn that 2,4-D corn alone could increase the herbicide's use by 30-fold, and soybeans will only exacerbate this. More widespread use of this volatile chemical will result in more drift, destroying nearby crops and creating unnecessary health risks for farmers and rural communities.
Say no to this pipeline of bad ideas» Join us in urging USDA to reject Dow's 2,4-D soybeans before the public comment period closes on September 11.
With 2,4-D-resistant corn already in the queue, Dow aims to get 2,4-D soy to market next year. And cotton is slated for 2015. These three crops dominate U.S. agriculture, blanketing well over 100 million acres of mono-cropped countryside and driving the pesticide market.
Monsanto's RoundUp Ready seed line has shown that the strategy of stacking seeds with herbicide-resistant traits doesn't work. But instead of abandoning this losing strategy, Dow is introducing more of the same, accelerating the pesticide treadmill. The costs of this strategy are clear:
- Damage to neighboring crops and farmers' livelihoods. 2,4-D drifts, both through spray drift and volatilization. This poses a very real threat to rural economies and farmers growing non-2,4-D-resistant crops. Conventional farmers will lose crops while organic farmers will lose both crops and certification, resulting in an economic unraveling of already-stressed rural communities.
- Health harms to farmers, rural communities and kids. 2,4-D is a reproductive toxicant, suspected endocrine disruptor and probable carcinogen. Children are particularly susceptible to its effects.
- More “superweeds.” 2,4-D-resistant weeds will arise and spread just as RoundUp-resistant “superweeds” have taken over farms and countryside in the Midwest and Southeast.
The stakes are high» This dangerous and antiquated herbicide shouldn’t be on the market, and we certainly should not be giving Dow license to profit from driving up use. We need to keep making noise on this one!